AMCP Format 4.1 includes new sections describing the evidence needs of HCDMs for unapproved products nearing the end of the product development pipeline, as well as unapproved uses of existing products for which FDA approval is being sought.
This forum identified key actions that can support access to and the appropriate management of treatments for rare diseases within the U.S. health care system.
During AMCP Legislative Day 2020, 40 AMCP members met with lawmakers in targeted congressional offices on AMCP’s key issues to explain the value of managed care pharmacy in the broader health care system.
More than 30 experts representing health plans, integrated delivery systems, health economists, providers, academicians, pharmaceutical manufacturers, and other professionals gathered for AMCP’s Partnership Forum to address the challenges in managing and providing timely access to rare and orphan disease therapies.
Read AMCP's summary of the Medicare Coverage of Innovative Technology proposed rule that would provide a national coverage pathway for breakthrough devices, including digital therapeutics.
